Our clinical trials

Our active immunisation for personalised anti-cancer vaccination is currently undergoing clinical investigations. A total of 34 patients, all having failed multiple standard therapies, have already been treated in our First-In-Human clinical study (Phase I), targeting patients with a variety of solid tumours, including pancreas, colon, head and neck, chordoma, prostate and ovarian. A phase II study in Head & Neck Squamous Cell Carcinoma (HNSCC) in collaboration with SAKK is currently ongoing.

For more information, follow the links below to the study listings on clinicaltrials.gov. Medical professionals may also email us at clinicaltrials@maxivax.ch for more information about study participation.